Review
doi: 10.2174/156802610790980611.
AMPK activators as novel therapeutics for type 2 diabetes
Affiliations
- PMID: 20180761
- DOI: 10.2174/156802610790980611
Item in Clipboard
Review
AMPK activators as novel therapeutics for type 2 diabetes
Curr Top Med Chem.
2010.
Abstract
AMPK is a potential target of metabolic diseases including obesity and type 2 diabetes. The activation of AMPK can lead to an increase of glucose uptake into muscle, decreased gluconeogenesis in liver, increased fatty acid oxidation in muscle and liver, decreased fatty acid synthesis in liver and adipose tissue, and increase mitochondrial biogenesis. Until now, many efforts from industrial and academia have been focused on searching novel agents that activate AMPK directly or indirectly. This review will discuss recent advances in the search for novel therapeutic agents that mediate their activity via AMPK activation.
Similar articles
-
AMPK activators--potential therapeutics for metabolic and other diseases.Acta Physiol (Oxf). 2009 May;196(1):175-90. doi: 10.1111/j.1748-1716.2009.01967.x. Epub 2009 Feb 19. Acta Physiol (Oxf). 2009. PMID: 19245659 Review.
-
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.Biochim Biophys Acta. 2010 Mar;1804(3):581-91. doi: 10.1016/j.bbapap.2009.09.012. Epub 2009 Sep 22. Biochim Biophys Acta. 2010. PMID: 19778642 Review.
-
Activators of AMPK: not just for type II diabetes.Future Med Chem. 2014 Jul;6(11):1325-53. doi: 10.4155/fmc.14.74. Future Med Chem. 2014. PMID: 25163002 Review.
-
Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes.Curr Drug Targets Immune Endocr Metabol Disord. 2002 Jul;2(2):119-27. Curr Drug Targets Immune Endocr Metabol Disord. 2002. PMID: 12476786 Review.
-
Targeting AMPK Signaling in the Liver: Implications for Obesity and Type 2 Diabetes Mellitus.Curr Drug Targets. 2022;23(11):1057-1071. doi: 10.2174/1389450123666220429082702. Curr Drug Targets. 2022. PMID: 36028937 Review.
Cited by
-
Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver.PLoS One. 2012;7(11):e48801. doi: 10.1371/journal.pone.0048801. Epub 2012 Nov 9. PLoS One. 2012. PMID: 23152807 Free PMC article.
-
Recent advances in understanding the anti-diabetic actions of dietary flavonoids.J Nutr Biochem. 2013 Nov;24(11):1777-89. doi: 10.1016/j.jnutbio.2013.06.003. Epub 2013 Sep 9. J Nutr Biochem. 2013. PMID: 24029069 Free PMC article. Review.
-
Hepatoprotective and Fat-Accumulation-Reductive Effects of Curcumin on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Curr Issues Mol Biol. 2025 Feb 27;47(3):159. doi: 10.3390/cimb47030159. Curr Issues Mol Biol. 2025. PMID: 40136412 Free PMC article. Review.
-
Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives.Br J Nutr. 2016 Apr 14;115(7):1129-44. doi: 10.1017/S0007114516000222. Epub 2016 Feb 16. Br J Nutr. 2016. PMID: 26879600 Free PMC article. Review.
-
Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.PLoS One. 2016 Jul 8;11(7):e0159191. doi: 10.1371/journal.pone.0159191. eCollection 2016. PLoS One. 2016. PMID: 27391974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
